Abstract
18F-FDG PET plays an important role in the evaluation of patients with lung malignancies but can lead to false-positive and falsenegative results. Very little is known about 18F-FDG PET scanning in amyloidosis. Methods: A computer-assisted search of medical records was conducted to identify subjects with pulmonary amyloidosis (confirmed by biopsy) who were seen at the Mayo Clinic during a 15-y period between January 1, 1997, and December 31, 2011, and had a PET scan available for current review. Results: Eighteen patients were diagnosed to have amyloidosis by lung biopsy (15 surgical, 2 transthoracic needle, and 1 bronchoscopic). The mean age of the patients was 64.8 y (range, 32-80 y). Seventeen patients had primary amyloidosis, including 5 with Sjögren syndrome, 1 with rheumatoid arthritis, and 1 with multiple myeloma. The most common abnormal findings on the chest CT scan were pulmonary nodules (n = 14), followed by cysts (n 5 6) and reticular opacities (n = 4). Eight patients had positive 18F-FDG PET results (intrathoracic 18F-FDG uptake), including 4 patients with coexisting mucosa-associated lymphoid tissue lymphoma (maximal standardized uptake value [SUVmax] range, 3.1-6.7) and 1 patient with a pleural plasmacytoma (SUVmax, 7.2); the remaining 3 patients had amyloid only (SUVmax range, 2.1-3.2). Ten patients with negative PET results included 3 additional patients with mucosa- associated lymphoid tissue lymphoma. Conclusion: Positive 18F-FDG PET results, especially with an SUVmax of more than 3, in patients with pulmonary amyloidosis should raise suspicion about associated lymphoma or plasmacytoma, but negative PET results do not exclude the presence of such neoplasms.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 565-568 |
| Number of pages | 4 |
| Journal | Journal of Nuclear Medicine |
| Volume | 55 |
| Issue number | 4 |
| DOIs | |
| State | Published - Apr 1 2014 |
Fingerprint
Keywords
- Amyloidosis
- B-cell
- Lymphoma
- Marginal zone
- Positronemission tomography
- Pulmonary nodule
- Sjögren's syndrome
ASJC Scopus subject areas
- Radiology Nuclear Medicine and imaging
- Medicine(all)
Cite this
18F-fdg pet scanning in pulmonary amyloidosis. / Baqir, Misbah; Lowe, Val; Yi, Eunhee S.; Ryu, Jay H.
In: Journal of Nuclear Medicine, Vol. 55, No. 4, 01.04.2014, p. 565-568.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - 18F-fdg pet scanning in pulmonary amyloidosis
AU - Baqir, Misbah
AU - Lowe, Val
AU - Yi, Eunhee S.
AU - Ryu, Jay H
PY - 2014/4/1
Y1 - 2014/4/1
N2 - 18F-FDG PET plays an important role in the evaluation of patients with lung malignancies but can lead to false-positive and falsenegative results. Very little is known about 18F-FDG PET scanning in amyloidosis. Methods: A computer-assisted search of medical records was conducted to identify subjects with pulmonary amyloidosis (confirmed by biopsy) who were seen at the Mayo Clinic during a 15-y period between January 1, 1997, and December 31, 2011, and had a PET scan available for current review. Results: Eighteen patients were diagnosed to have amyloidosis by lung biopsy (15 surgical, 2 transthoracic needle, and 1 bronchoscopic). The mean age of the patients was 64.8 y (range, 32-80 y). Seventeen patients had primary amyloidosis, including 5 with Sjögren syndrome, 1 with rheumatoid arthritis, and 1 with multiple myeloma. The most common abnormal findings on the chest CT scan were pulmonary nodules (n = 14), followed by cysts (n 5 6) and reticular opacities (n = 4). Eight patients had positive 18F-FDG PET results (intrathoracic 18F-FDG uptake), including 4 patients with coexisting mucosa-associated lymphoid tissue lymphoma (maximal standardized uptake value [SUVmax] range, 3.1-6.7) and 1 patient with a pleural plasmacytoma (SUVmax, 7.2); the remaining 3 patients had amyloid only (SUVmax range, 2.1-3.2). Ten patients with negative PET results included 3 additional patients with mucosa- associated lymphoid tissue lymphoma. Conclusion: Positive 18F-FDG PET results, especially with an SUVmax of more than 3, in patients with pulmonary amyloidosis should raise suspicion about associated lymphoma or plasmacytoma, but negative PET results do not exclude the presence of such neoplasms.
AB - 18F-FDG PET plays an important role in the evaluation of patients with lung malignancies but can lead to false-positive and falsenegative results. Very little is known about 18F-FDG PET scanning in amyloidosis. Methods: A computer-assisted search of medical records was conducted to identify subjects with pulmonary amyloidosis (confirmed by biopsy) who were seen at the Mayo Clinic during a 15-y period between January 1, 1997, and December 31, 2011, and had a PET scan available for current review. Results: Eighteen patients were diagnosed to have amyloidosis by lung biopsy (15 surgical, 2 transthoracic needle, and 1 bronchoscopic). The mean age of the patients was 64.8 y (range, 32-80 y). Seventeen patients had primary amyloidosis, including 5 with Sjögren syndrome, 1 with rheumatoid arthritis, and 1 with multiple myeloma. The most common abnormal findings on the chest CT scan were pulmonary nodules (n = 14), followed by cysts (n 5 6) and reticular opacities (n = 4). Eight patients had positive 18F-FDG PET results (intrathoracic 18F-FDG uptake), including 4 patients with coexisting mucosa-associated lymphoid tissue lymphoma (maximal standardized uptake value [SUVmax] range, 3.1-6.7) and 1 patient with a pleural plasmacytoma (SUVmax, 7.2); the remaining 3 patients had amyloid only (SUVmax range, 2.1-3.2). Ten patients with negative PET results included 3 additional patients with mucosa- associated lymphoid tissue lymphoma. Conclusion: Positive 18F-FDG PET results, especially with an SUVmax of more than 3, in patients with pulmonary amyloidosis should raise suspicion about associated lymphoma or plasmacytoma, but negative PET results do not exclude the presence of such neoplasms.
KW - Amyloidosis
KW - B-cell
KW - Lymphoma
KW - Marginal zone
KW - Positronemission tomography
KW - Pulmonary nodule
KW - Sjögren's syndrome
UR - http://www.scopus.com/inward/record.url?scp=84901306692&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84901306692&partnerID=8YFLogxK
U2 - 10.2967/jnumed.113.130823
DO - 10.2967/jnumed.113.130823
M3 - Article
C2 - 24556593
AN - SCOPUS:84901306692
VL - 55
SP - 565
EP - 568
JO - Journal of Nuclear Medicine
JF - Journal of Nuclear Medicine
SN - 0161-5505
IS - 4
ER -